A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
(BLAZE-1 Trial)

Recruiting in Palo Alto (17 mi)

+160 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Eli Lilly and Company

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and LY3832479. Enrollment began on March 31, 2021, and completed on September 24, 2021. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113. Enrollment began on August 19, 2022, and completed on February 21, 2023.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

Inclusion Criteria

You are currently taking medication that lowers your immune system.

Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion

Are males or females, including pregnant females who agree to contraceptive requirements

See 66 more

Treatment Details

Interventions

LY3819253 (Monoclonal Antibodies)
LY3832479 (Monoclonal Antibodies)
LY3853113 (Monoclonal Antibodies)
Placebo (Other)

Participant Groups

5Treatment groups

Experimental Treatment

Placebo Group

Group I: LY3853113 (Pediatric Addendum, Arm 23)Experimental Treatment1 Intervention

LY3853113 dose based upon weight (Weight Group: ≥3.3 to ≤12 kg = 3 mg/kg dose, \>12 to ≤20 kg = 43.75 mg dose, \>20 to \<40 kg = 87.5 mg dose, ≥40 kg = 175 mg dose) administered IV.

Group II: LY3819253 + LY3832479 (Pediatric Addendum, Arm 22)Experimental Treatment2 Interventions

LY3819253 dose based upon weight (weight Group: ≥40 kilogram (kg) = 700 mg dose, \>20 kg to \<40 kg = 350 mg dose, \>12 kg to 20 kg = 175 mg dose and 1.5 kg to 12 kg = 15 mg/kg dose) and LY3832479 dose based upon weight (weight Group: ≥40 kg = 1400 mg dose, \>20 kg to \<40 kg = 700 mg dose, \>12 kg to 20 kg = 350 mg dose and 1.5 kg to 12 kg = 30 mg/kg dose) administered IV.

Group III: LY3819253 + LY3832479Experimental Treatment2 Interventions

350 mg, 700 mg, 2800 mg LY3819253 + 700 mg, 1400 mg, 2800 mg LY3832479 administered IV or subcutaneously (SQ)

Group IV: LY3819253Experimental Treatment1 Intervention

700 mg, 2800 mg, 7000 mg, LY3819253 administered intravenously (IV)

Group V: PlaceboPlacebo Group1 Intervention

Placebo administered IV